MX2015006386A - Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met). - Google Patents

Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).

Info

Publication number
MX2015006386A
MX2015006386A MX2015006386A MX2015006386A MX2015006386A MX 2015006386 A MX2015006386 A MX 2015006386A MX 2015006386 A MX2015006386 A MX 2015006386A MX 2015006386 A MX2015006386 A MX 2015006386A MX 2015006386 A MX2015006386 A MX 2015006386A
Authority
MX
Mexico
Prior art keywords
met
egfr
binding molecules
type iii
fibronectin type
Prior art date
Application number
MX2015006386A
Other languages
English (en)
Other versions
MX369334B (es
Inventor
Mark Anderson
Karyn O'neil
Kristen Picha
Linus Hyun
Steven Jacobs
Michael Diem
Ricardo Attar
Alastair King
Donna Klein
Sheri Moores
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50776675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2015006386A publication Critical patent/MX2015006386A/es
Publication of MX369334B publication Critical patent/MX369334B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen moléculas monoespecíficas y biespecíficas que contienen el dominio FN3 de EGFR y/o c-Met, nucleótidos aislados que codifican las moléculas, vectores, células hospederas, y métodos para hacer las mismas; estas moléculas monoespecíficas y biespecíficas que contienen el dominio FN3 de EGFR y/o c-Met son útiles en la generación de composiciones terapéuticas para tratar y diagnosticar enfermedades y trastornos incluyendo el cáncer.
MX2015006386A 2012-11-21 2013-11-21 Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met). MX369334B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728906P 2012-11-21 2012-11-21
US201261728912P 2012-11-21 2012-11-21
US201261728914P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
PCT/US2013/071267 WO2014081944A2 (en) 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules

Publications (2)

Publication Number Publication Date
MX2015006386A true MX2015006386A (es) 2015-12-03
MX369334B MX369334B (es) 2019-11-05

Family

ID=50776675

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006386A MX369334B (es) 2012-11-21 2013-11-21 Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2019013117A MX2019013117A (es) 2012-11-21 2015-05-20 Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013117A MX2019013117A (es) 2012-11-21 2015-05-20 Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).

Country Status (22)

Country Link
US (4) US9695228B2 (es)
EP (3) EP4023670A1 (es)
JP (3) JP6393270B2 (es)
KR (2) KR102210196B1 (es)
CN (5) CN108546300B (es)
AU (3) AU2013347952B2 (es)
CA (1) CA2891485A1 (es)
CL (1) CL2015001353A1 (es)
CY (1) CY2022010I2 (es)
EA (2) EA035559B1 (es)
ES (2) ES2899292T3 (es)
HK (1) HK1215680A1 (es)
IL (2) IL238730B (es)
MX (2) MX369334B (es)
MY (1) MY176820A (es)
NI (1) NI201500070A (es)
NZ (1) NZ708349A (es)
PH (1) PH12015501134A1 (es)
SG (2) SG10201707488TA (es)
UA (1) UA118096C2 (es)
WO (1) WO2014081944A2 (es)
ZA (1) ZA201504427B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102053674B1 (ko) * 2012-05-25 2019-12-09 얀센 바이오테크 인코포레이티드 비-천연 컨센서스 알부민 결합 도메인
CA3182876A1 (en) 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102275676B1 (ko) 2012-11-21 2021-07-12 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
US10179808B2 (en) * 2013-01-25 2019-01-15 Janssen Biotech, Inc. Kv1.3 antagonists and methods of use
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
CN105899226B (zh) 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN116832890A (zh) * 2015-04-06 2023-10-03 中尺度技术有限责任公司 操作测定系统的方法及ecl免疫测定系统
JP7019423B2 (ja) * 2015-05-06 2022-02-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
EP3292222A4 (en) 2015-05-06 2018-10-17 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
US20170002058A1 (en) * 2015-06-30 2017-01-05 Regents Of The University Of Minnesota Compositions and methods that involve protein scaffolds that specifically bind to hepatocyte growth factor receptor
JP2018520675A (ja) * 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
KR102461666B1 (ko) 2016-06-03 2022-11-01 얀센 바이오테크 인코포레이티드 혈청 알부민 결합 피브로넥틴 iii 형 도메인
AU2017281083B2 (en) * 2016-06-21 2022-01-27 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
JP7104703B2 (ja) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
AU2018304173A1 (en) * 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
JP2022547274A (ja) 2019-09-16 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
US20240304816A1 (en) 2021-01-29 2024-09-12 Lg Chem, Ltd. Electrode
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
US7842476B2 (en) 2002-09-06 2010-11-30 Isogenica Limited In vitro peptide expression library
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
US7932026B2 (en) 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
CN101636410A (zh) * 2006-11-22 2010-01-27 雅达思 基于酪氨酸激酶受体（包括igf-ir）的工程化蛋白质的靶向治疗剂
EP2076289B1 (en) 2007-04-13 2014-11-12 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
EP2215115A1 (en) * 2007-11-08 2010-08-11 The University of Chicago Molecular affinity clamp technology and uses thereof
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
AU2008343595A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. A human non-antibody peptide or protein phage library
MX2010008874A (es) 2008-02-14 2010-09-22 Bristol Myers Squibb Co Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
CL2009000542A1 (es) 2008-03-06 2010-11-05 Genentech Inc Uso de un antagonista de c-met y egfr de formula general i para preparar un medicamento para tratar el cancer.
TW201002346A (en) 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
EP2274331B1 (en) * 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
CN102099373A (zh) * 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
MX2011003363A (es) 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
WO2010093627A2 (en) * 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
CN102361884A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
JP6055312B2 (ja) 2010-03-10 2017-01-11 ゲンマブ エー／エス Ｃ−ｍｅｔに対するモノクローナル抗体
CA2795325A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
CN103097417B (zh) 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
EP2560683B2 (en) 2010-04-23 2022-07-20 F. Hoffmann-La Roche AG Production of heteromultimeric proteins
RU2603272C2 (ru) 2010-04-30 2016-11-27 Янссен Байотек, Инк. Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US9200273B2 (en) 2011-09-27 2015-12-01 Janssen Biotech, Inc. Fibronectin type III repeat based protein scaffolds with alternative binding surfaces
KR102053674B1 (ko) 2012-05-25 2019-12-09 얀센 바이오테크 인코포레이티드 비-천연 컨센서스 알부민 결합 도메인
CA3182876A1 (en) 2012-11-21 2014-05-30 Janssen Biotech, Inc. Bispecific egfr/c-met antibodies
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN105899226B (zh) * 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子

Also Published As

Publication number Publication date
PH12015501134B1 (en) 2015-08-17
JP2022008534A (ja) 2022-01-13
CY2022010I1 (el) 2022-07-22
US9725497B2 (en) 2017-08-08
IL238730A0 (en) 2015-06-30
EA201590998A1 (ru) 2016-02-29
EA036054B1 (ru) 2020-09-21
JP6393270B2 (ja) 2018-09-19
CN106977606B (zh) 2021-08-27
CN107098975A (zh) 2017-08-29
ES2899292T3 (es) 2022-03-10
CL2015001353A1 (es) 2015-10-02
WO2014081944A3 (en) 2014-07-17
US20140155325A1 (en) 2014-06-05
US9695228B2 (en) 2017-07-04
CN104955473B (zh) 2018-05-18
US20170305997A1 (en) 2017-10-26
US20140155326A1 (en) 2014-06-05
CN107098975B (zh) 2021-11-05
ZA201504427B (en) 2017-11-29
AU2020267284B2 (en) 2022-03-31
AU2020267284A1 (en) 2020-12-10
JP2016504291A (ja) 2016-02-12
US20210206825A1 (en) 2021-07-08
KR20150087340A (ko) 2015-07-29
CN108546300B (zh) 2022-03-15
EP2922566A2 (en) 2015-09-30
EP3485901B1 (en) 2021-10-13
IL238730B (en) 2019-12-31
AU2018241106A1 (en) 2018-10-25
KR102210196B1 (ko) 2021-02-01
UA118096C2 (uk) 2018-11-26
JP7015223B2 (ja) 2022-02-02
EP2922566B1 (en) 2018-10-03
EP4023670A1 (en) 2022-07-06
NI201500070A (es) 2015-09-21
EA201791577A1 (ru) 2017-11-30
SG11201503942RA (en) 2015-06-29
AU2013347952B2 (en) 2018-07-12
MX369334B (es) 2019-11-05
EP2922566A4 (en) 2016-10-26
CY2022010I2 (el) 2022-07-22
CN113667020A (zh) 2021-11-19
JP2019033748A (ja) 2019-03-07
PH12015501134A1 (en) 2015-08-17
IL270852A (en) 2020-01-30
CA2891485A1 (en) 2014-05-30
HK1215680A1 (zh) 2016-09-09
NZ748444A (en) 2020-10-30
MY176820A (en) 2020-08-21
MX2019013117A (es) 2019-12-16
EA035559B1 (ru) 2020-07-07
AU2018241106B2 (en) 2020-08-20
WO2014081944A9 (en) 2015-09-17
WO2014081944A2 (en) 2014-05-30
EP3485901A1 (en) 2019-05-22
AU2013347952A1 (en) 2015-05-28
CN108546300A (zh) 2018-09-18
US10954284B2 (en) 2021-03-23
IL270852B (en) 2020-09-30
NZ708349A (en) 2020-10-30
ES2696148T3 (es) 2019-01-14
SG10201707488TA (en) 2017-10-30
KR20210013324A (ko) 2021-02-03
CN106977606A (zh) 2017-07-25
CN104955473A (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
PH12015501134B1 (en) Egfr and c-met-fibronectin type iii domain binding molecules
MY171038A (en) Bispecific antigen binding molecules
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
MY184889A (en) T cell activating bispecific antigen binding molecules
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
PH12016502151A1 (en) Humanized antibodies against ceacam1
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
TN2011000524A1 (en) Antibodies specific to cadherin -17
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
EA202090841A2 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
BR112015011593A2 (pt) Moléculas de ligação ao domínio de fibronectina tipo iii de egfr e c-met
TN2014000207A1 (en) Anti il-36r antibodies
WO2014150819A3 (en) Cancer biomarkers and methods of treating cancer

Legal Events

Date Code Title Description
FG Grant or registration